CN108812548A - The method and purposes of brucella vaccine immune cattle - Google Patents
The method and purposes of brucella vaccine immune cattle Download PDFInfo
- Publication number
- CN108812548A CN108812548A CN201811096575.2A CN201811096575A CN108812548A CN 108812548 A CN108812548 A CN 108812548A CN 201811096575 A CN201811096575 A CN 201811096575A CN 108812548 A CN108812548 A CN 108812548A
- Authority
- CN
- China
- Prior art keywords
- vaccine
- brucella
- immune
- immune cattle
- cattle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/02—Breeding vertebrates
Abstract
The present invention provides the methods and purposes of a kind of brucella vaccine immune cattle, are related to technical field of vaccines.The method of brucella vaccine immune cattle provided by the invention, including it is first primary using vaccine A immune cattle, then reuse vaccine B immune cattle at least once；Wherein vaccine A is Brucella live vaccine, and immunizing dose is 60-150 hundred million CFU/ part；Vaccine B includes at least one of inactivated vaccine, subunit vaccine, recombinant protein vaccine, polypeptide vaccine and DNA vaccination of brucella.Head exempts from the humoral and cellular immune response with low dosage live vaccine immune activation body; it is secondary to body progress or repeatedly immune to reuse non-live vaccine; the immunological memory of body can be strengthened; the stress reaction of ox and the infection risk of operator are reduced while effective protection is provided, alleviate it is existing in the prior art lack a kind of couple of people it is safe while again can effectively immune cattle brucella vaccine immune cattle method the technical issues of.
Description
Technical field
The present invention relates to technical field of vaccines, more particularly, to the method and purposes of a kind of brucella vaccine immune cattle.
Background technique
Brucellosis (Brucellosis, abbreviation brucellosis) is also known as Mediterranean remittent fever, Malta fever or wave
Heat is that a kind of popularity range as caused by brucella (Brucella) is wide, it is anti-to seriously endanger infection-metamorphosis of human and livestock health
Answering property disease.Brucella (brucella) is the quarter butt dress bacterium of Gram-negative, long in single arrangement, it is rare at
Are not formed by gemma or pod membrane, is not moved for, short chain or string-like arrangement, atrichia.Zoogenetic infection brucellosis generally goes out
The now symptoms such as miscarriage, infertile, orchitis and arthritis, the clinical characters of people's infection are mostly persistent infection, heat wave wave, more
Sweat, arthralgia etc., and may recur or leave serious sequelae.Brucellosis restricts the development of animal husbandry and threatens public
It is safe and healthy.
Brucellosis is a kind of infectious diseases common to human beings and animals, and domestic animal, poultry, wild animal and domesticated animal can be used as place
Main, brucellosis is often first propagated in domestic animal or wild animal, then feeds through to the mankind.Wherein, sheep, ox and pig are in cloth Shandong
It is mostly important on Salmonella disease epidemiology, and major source of infection related with the mankind.Brucella can cause a disease throughout the year,
It but is more with domestic animal miscarriage season.In country variant and area or even a national different zones, various animals are as infection
The meaning in source is different.The main infection animal of different regions is different, and New Zealand, Australia and US West are mostly drawn by sheep
It rises；European northern and middle part country is by Niu Yinqi；The certain states in Southeast Asia and North America, pig is major source of infection.In China north
Square most area sheep is major source of infection, some local oxen are major source of infection, and the south such as Guangdong, Guangxi provinces and regions pig is main
The infection sources.Brucellosis Patients can discharge brucella from milk, fester, excrement and urine.
Animal carrier is the major source of infection of other animals and humans brucellosis.After brucella invades body, energy
Cause whole body reticuloendothelial system hyperplasia, often with bacteremia and toxaemia.Although brucella can invade any of body
Position, but attached most importance to especially with damaging bone and joint.Damage of the brucella to nervous system is also more serious, and whole body can be caused weary
The symptoms such as power, fatigue, hidrosis, insomnia, headache, dizziness and easy excitement.Brucella can also cause angiocarpy, endocrine system,
The damage of urogenital system and immune system.
In view of heavy losses caused by brucellosis, corresponding prevention and control and root have been formulated in many countries and regions in the world
Except plan, had great importance in the process using vaccine immunity, what especially in brucellosis prevalence, the situation is tense
Area.
Early stage was once used for the cloth disease prevention and control of humans and animals using inactivated vaccine, then by the better weak poison epidemic disease living of immune efficacy
Seedling substitution.Using live vaccination, there is more unfavorable factor：First is that often being generated after animal inoculation pvaccination live vaccine more serious
Stress reaction；Second is that containing the viable bacteria of higher concentration in live vaccine dosage, immune operation personnel have higher infection risk；
Third is that once inoculation live vaccine immune effect may be bad.Mainly there are A19 and S2 suitable for the brucella vaccine of ox at present,
Middle A19 virulence is stronger, and dosage when immune cattle is larger, it usually needs 600-800 hundred million CFU/ part, therefore to the ox being immunized
Toxic side effect is easily caused, and is easy infection inoculation personnel；S2 vaccine immunogenicity is poor, cannot play good protection and make
With.
Therefore, while a kind of couple of people is safe can the method for brucella vaccine immune cattle of effectively immune cattle be current
The problem of urgent need to resolve.
In view of this, the present invention is specifically proposed.
Summary of the invention
A kind of method that the purpose of the present invention first is designed to provide brucella vaccine immune cattle, to alleviate existing skill
Lack present in art a kind of couple of people it is safe while can effectively immune cattle brucella vaccine immune cattle method skill
Art problem.
The purpose of the present invention second is designed to provide a kind of method of above-mentioned brucella vaccine immune cattle in cloth Lu Shi
Purposes in bacterium prevention and control.
In order to solve the above technical problems, spy of the present invention adopts the following technical scheme that：
A kind of method of brucella vaccine immune cattle, the immunization method include first using vaccine A immune cattle primary, so
After reuse vaccine B immune cattle at least once；
Wherein, the vaccine A is Brucella live vaccine；The immunizing dose of the Brucella live vaccine is 60-150 hundred million
CFU/ parts；
The vaccine B includes inactivated vaccine, subunit vaccine, recombinant protein vaccine, polypeptide vaccine and the DNA of brucella
At least one of vaccine.
Preferably, the dosage of the Brucella live vaccine is 80-130 hundred million CFU/ part.
Preferably, the dosage of the Brucella live vaccine is 90-110 hundred million CFU/ part.
Preferably, the vaccine A includes Brucella abortus vaccine A19, Brucella melitensis vaccine Rev.1, Brucella suis
Vaccine S2, Brucella abortus 45/20 or rough type B. abortus strain 51.
Preferably, vaccine B immune cattle is reused after first time immune cattle 10-40 days, preferably 15-35 days, more preferable 20-30
Day.
Preferably, using vaccine B immune cattle 1-3 times.
Preferably, primary using vaccine B immune cattle, the vaccine B is inactivated vaccine.
Preferably, the inactivated vaccine is the inactivated vaccine that will be obtained after vaccine A inactivation.
Preferably, the dosage of the brucella inactivated vaccine is 400-600 hundred million CFU/ part, brucella inactivated vaccine
Dosage according to before vaccine inactivation viable count calculate；
Preferably, the dosage of the brucella inactivated vaccine is 450-550 hundred million CFU/ part；
Preferably, the dosage of the brucella inactivated vaccine is 480-500 hundred million CFU/ part.
The present invention also provides a kind of methods of above-mentioned brucella vaccine immune cattle in the brucella prevention and control of ox
Purposes.
Compared with prior art, the present invention has the advantages that：
The method of brucella vaccine immune cattle provided by the invention, including it is first primary using vaccine A immune cattle, then again
At least once using vaccine B immune cattle；Wherein vaccine A is Brucella live vaccine；The immunizing dose of the Brucella live vaccine
For 60-150 hundred million CFU/ part；Vaccine B includes the inactivated vaccine, subunit vaccine, recombinant protein vaccine, polypeptide epidemic disease of brucella
At least one of seedling and DNA vaccination.
The method of brucella vaccine immune cattle provided by the invention is different from conventional skill using repeatedly immune strategy
(600-800 hundred million CFU/ part) in art using single vaccine large dosage is treated immune cattle and is immunized, and the present invention is different
The immune stage treats immune cattle using different types of vaccine and is immunized, and head exempts from living with low dosage (60-150 hundred million CFU/ part)
Vaccine immunity activates the humoral and cellular immune response of body, reuses non-live vaccine and carries out secondary or repeatedly immune, reinforcing to body
Immunity of organism memory, reduces the stress reaction of ox and the infection risk of operator while providing effective protection.
Purposes of the method for above-mentioned brucella vaccine immune cattle provided by the invention in the brucella prevention and control of ox, can
Effectively to improve immune cattle to the immunocompetence of brucella, and since the above method uses low dosage in first immunisation
Live bacterial vaccines it is immune, therefore, can reduce and the risk that immune personnel infect brucella is implemented to ox, enhance cloth Lu Shi
The safety of personnel in bacterium disease prevention and control.
Detailed description of the invention
It, below will be to specific in order to illustrate more clearly of the specific embodiment of the invention or technical solution in the prior art
Embodiment or attached drawing needed to be used in the description of the prior art be briefly described, it should be apparent that, it is described below
Attached drawing is some embodiments of the present invention, for those of ordinary skill in the art, before not making the creative labor
It puts, is also possible to obtain other drawings based on these drawings.
Fig. 1 is that continuous Temperature changing in cow 14 days is immunized after cow in the embodiment of the present invention 1 and comparative example 1 for the first time；
Fig. 2 is continuous Temperature changing in cow 14 days after 1 secondary immunity cow of the embodiment of the present invention.
Specific embodiment
Technical solution of the present invention is clearly and completely described below in conjunction with drawings and examples, it is clear that retouched
The embodiment stated is a part of the embodiment of the present invention, instead of all the embodiments.Based on the embodiments of the present invention, this field
Those of ordinary skill's every other embodiment obtained without making creative work, belongs to protection of the present invention
Range.The person that is not specified actual conditions in embodiment, carries out according to conventional conditions or manufacturer's recommended conditions.Agents useful for same or
Production firm person is not specified in instrument, is the conventional products that can be obtained by commercially available purchase.
The present invention provides a kind of method of brucella vaccine immune cattle, the immunization method includes first using vaccine A
Immune cattle is primary, then reuses vaccine B immune cattle at least once；
Wherein, the vaccine A is Brucella live vaccine；The immunizing dose of the Brucella live vaccine is 60-150 hundred million
CFU/ parts；
The vaccine B includes inactivated vaccine, subunit vaccine, recombinant protein vaccine, polypeptide vaccine and the DNA of brucella
At least one of vaccine.
The method of brucella vaccine immune cattle provided by the invention is different from conventional skill using repeatedly immune strategy
(600-800 hundred million CFU/ part) in art using single vaccine large dosage is treated immune cattle and is immunized, and the present invention is different
The immune stage treats immune cattle using different types of vaccine and is immunized, and head exempts from living with low dosage (60-150 hundred million CFU/ part)
Vaccine immunity activates the humoral and cellular immune response of body, reuses non-live vaccine and carries out secondary or repeatedly immune, reinforcing to body
Immunity of organism memory, reduces the stress reaction of ox and the infection risk of operator while providing effective protection.
The live vaccine that the present invention is used in first immunisation can be commercially available Brucella live vaccine, such as can be but
It is not limited to Brucella abortus vaccine A19, Brucella melitensis vaccine Rev.1, Brucella suis vaccine S2, Brucella abortus 45/
20 or rough type B. abortus strain 51 etc..
Brucella abortus vaccine A19, that is, S19 vaccine, S19 plants《Chinese veterinary pharmacopoeia》In be referred to as A19 plants, A19 vaccine can
To provide preferable protection for ox, which is smooth type, and LPS contains O- side chain, can continue stimulation body and generate antibody；
Brucella melitensis vaccine Rev.1 derives from B.melitensis separation strains, has streptomycin resistance.It is equal to ox, Brucella melitensis
With immune protective efficiency；Brucella suis vaccine S2 to pig, ox, sheep can generate it is good be immunized, can put into drink water in be administered；
Brucella abortus 45/20 is to separate out of infected cattle body nineteen twenty-two, the attenuated strain of the rough type obtained after passing on by cavy 20 times,
The vaccine can provide preferable protection to cavy and ox；51 vaccine strain of rough type B. abortus strain is initially by smooth type
2308 plants of Brucella abortus are passed on repeatedly in vitro, and are obtained through the screening of rifampin and mycin.It is understood that when above-mentioned
Vaccine can also include adjuvant when being commercially available vaccine, and the present invention does not limit the use of adjuvant, acceptable adjuvant in this field
?.
Inactivated vaccine, subunit's epidemic disease can be used when reusing non-live vaccine and carrying out secondary or repeatedly immune to body
At least one of seedling, recombinant protein vaccine, polypeptide vaccine and DNA vaccination.
The live vaccine that inactivated vaccine uses when can choose first immunisation inactivates inactivation, uses as inactivated vaccine,
It can choose existing inactivated vaccine.Since identical immunogene can guarantee the similar immune response of duplicate activation,
Therefore preferably first by vaccine A through inactivation treatment, then it is re-used as inactivated vaccine use.In some alternative embodiments, it goes out
Processing living is preferably inactivated using inactivator, and the extinguishing chemical for example can be but be not limited to formaldehyde, acetyl group aziridine, two
Aziridine, glycidaldehyde, it is preferable to use 0.1%-0.3% formalin-killed vaccine A.
Recombinant protein vaccine is the purpose antigen of certain virus is gene constructed on expression vector, the expression that will have been constructed
Protein carrier is transformed into bacterium, in yeast or lactation ox or insect cell, under certain inductive condition, gives expression to a large amount of anti-
Former albumen passes through the vaccine prepared after purification.
Subunit vaccine passes through chemical breakdown or has the protein-hydrolysis process of controlling, extracts the spy of bacterium, virus
Different protein structure, what is filtered out has vaccine made of immunocompetent segment.Subunit vaccine is that pathogenic bacteria are main
Vaccine made of component existing for protective immunity original, is also component vaccine.Exempt from recombinant protein vaccine or subunit vaccine
Epidemic focus for example can be but be not limited to molecular chaperones DanK, transferrins Bfr, outer membrane protein, Cu-Zn superoxide dismutase
Enzyme, SodC, Tig, SurA, BLS, p39 or sugared kinases etc..
DNA vaccination is usually the recombinant plasmid containing brucella protective antigens, can also contain some cells simultaneously
To enhance immune response, the DNA vaccination for example can be but be not limited to containing following gene factor code gene：Ribosomes
It is L7/L12, periplasmic albumen p39 and ferritin, Cu-Zn superoxide dismutase, periplasmic albumen p39 and ferritin, outer
Memebrane protein Omp31, lumazine synzyme BLS etc..
In some alternative embodiments, the dosage of the Brucella live vaccine for example can be but be not limited to
For but be not limited to 60,65,70,75,80,85,90,95,100,105,110,115,125,130,135,140,145 or 150
Hundred million CFU/ part；Preferred dose is 80-130 hundred million CFU/ part；More preferably 90-110 hundred million CFU/ part.First immunisation live vaccine
Dosage suitable adjustment can be carried out according to the live vaccine of selection, can also type according to the vaccine of follow-up immunization, dosage
It is adjusted with immune number.
In some alternative embodiments, first time epidemic disease ox reuses vaccine B immune cattle, preferably 15-35 after 10-40 days
Day, it is 20-30 days more preferable.Since adaptive immune response needs at least one week time that can activate, secondary immunity
Time should not be with the first immunisation time at a distance of excessively close, the time of secondary immunity is also unfavorable for the immune note of reinforcing body too late
Recall, present embodiment is found through experiments that the effect that secondary immunity is carried out between first immunisation 10-40 days is best, it is possible to understand that
, the type and dosage for the live vaccine that the time of secondary immunity can also select according to first immunisation are adjusted.
In some alternative embodiments, using vaccine B immune cattle 1-3 times, such as it can be but be not limited to but not
It is limited to be 1 time, 2 times or 3 times.When the vaccine B selection preferable vaccine of immunogenicity, such as appropriate can be reduced when inactivated vaccine
Immune time, when vaccine B is selected safety is higher but recombinant vaccine or DNA vaccination that immunogenicity is poor when can be appropriate
The immune number of increase, this test discovery vaccine B, which is immunized 1-3 times, to be advisable.
In a preferred scheme of the invention, immune cattle as follows, immune effect is preferable, immune time two
Secondary, first immunisation is live vaccine (60-150 hundred million CFU/ part).Two exempt from the time be first immunisation after 20-30 days, use inactivated vaccine
Immune, inactivated vaccine uses the live vaccine used when the first immunisation of formalin-inactivated；The dosage of inactivated vaccine is 400- before inactivating
60000000000 CFU/ part.
In some alternative embodiments, the dosage of the brucella inactivated vaccine is 400-600 hundred million CFU/ part,
Such as can be but be not limited to 400,410,420,430,440,450,460,470,480,490,500,510,520,530,
540,550,560,570,580,590 or 60,000,000,000 CFU/ parts, preferably 450-550 hundred million CFU/ part；More preferable 480-500 hundred million
CFU/ parts；The dosage of brucella inactivated vaccine is calculated according to the viable count before vaccine inactivation.By adjusting secondary immunity
Immunizing dose can advanced optimize immune effect.
In some preferred embodiments, the present invention also provides a kind of kits, first using vaccine A and vaccine B as group
It closes vaccine to be contained in kit, ox is inoculated with facilitating.It preferably, can also be comprising being used when inoculation in the kit
In the equipment such as syringe and sterilizing article etc. of inoculation, the reagent for inactivating to live vaccine, preferably formaldehyde can also be included.
The present invention also provides a kind of purposes of above-mentioned immunization method in the brucella prevention and control of ox.By above-mentioned immune side
Method is applied to brucellosis prevention and control, can effectively improve immune cattle to the immunocompetence of brucella, and due to above-mentioned
Method is immune using the live bacterial vaccines of low dosage in first immunisation, therefore, can reduce and implement immune personnel's infection to ox
The risk of brucella enhances the safety of brucellosis prevention and control.
Beneficial effects of the present invention are further illustrated below with reference to preferred embodiment.
Embodiment 1
A kind of method for present embodiments providing brucella vaccine immune cattle, includes the following steps：
(a) first immunisation：Immune cattle brucella vaccine A19 vaccine inoculates 10,000,000,000 CFU/ part；
(b) secondary immunity：Brucella abortus vaccine A19 is used into formalin-inactivated, by inactivation after first immunisation 25 days
Brucella abortus vaccine A19, subcutaneous injection immune cattle, immunizing dose is 50,000,000,000 CFU/ part, according to the work before vaccine inactivation
Bacterium number calculates.
Embodiment 2
A kind of method for present embodiments providing brucella vaccine immune cattle, includes the following steps：
(a) first immunisation：Immune cattle brucella vaccine A19 vaccine inoculates 9,000,000,000 CFU/ part；
(b) secondary immunity：Brucella abortus vaccine A19 is used into formalin-inactivated, by inactivation after first immunisation 30 days
Brucella abortus vaccine A19, subcutaneous injection immune cattle, immunizing dose is 48,000,000,000 CFU/ part, according to the work before vaccine inactivation
Bacterium number calculates.
Embodiment 3
A kind of method for present embodiments providing brucella vaccine immune cattle, includes the following steps：
(a) first immunisation：Immune cattle brucella vaccine A19 vaccine inoculates 11,000,000,000 CFU/ part；
(b) secondary immunity：Brucella abortus vaccine A19 is used into formalin-inactivated, by inactivation after first immunisation 20 days
Brucella abortus vaccine A19, subcutaneous injection immune cattle, immunizing dose is 50,000,000,000 CFU/ part, according to the work before vaccine inactivation
Bacterium number calculates.
Embodiment 4
A kind of method for present embodiments providing brucella vaccine immune cattle, includes the following steps：
(a) first immunisation：Immune cattle brucella vaccine A19 vaccine inoculates 8,000,000,000 CFU/ part；
(b) secondary immunity：Brucella abortus vaccine A19 is used into formalin-inactivated, by inactivation after first immunisation 35 days
Brucella abortus vaccine A19, subcutaneous injection immune cattle, immunizing dose is 45,000,000,000 CFU/ part, according to the work before vaccine inactivation
Bacterium number calculates.
Embodiment 5
A kind of method for present embodiments providing brucella vaccine immune cattle, includes the following steps：
(a) first immunisation：Immune cattle brucella vaccine A19 vaccine inoculates 13,000,000,000 CFU/ part；
(b) secondary immunity：Brucella abortus vaccine A19 is used into formalin-inactivated, by inactivation after first immunisation 15 days
Brucella abortus vaccine A19, subcutaneous injection immune cattle, immunizing dose is 50,000,000,000 CFU/ part, according to the work before vaccine inactivation
Bacterium number calculates.
Embodiment 6
A kind of method for present embodiments providing brucella vaccine immune cattle, includes the following steps：
(a) first immunisation：Immune cattle brucella vaccine A19 vaccine inoculates 6,000,000,000 CFU/ part；
(b) secondary immunity：Brucella abortus vaccine A19 is used into formalin-inactivated, by inactivation after first immunisation 40 days
Brucella abortus vaccine A19, subcutaneous injection immune cattle, immunizing dose is 40,000,000,000 CFU/ part, according to the work before vaccine inactivation
Bacterium number calculates.
Embodiment 7
A kind of method for present embodiments providing brucella vaccine immune cattle, includes the following steps：
(a) first immunisation：Immune cattle brucella vaccine A19 vaccine inoculates 15,000,000,000 CFU/ part；
(b) secondary immunity：Brucella abortus vaccine A19 is used into formalin-inactivated, by inactivation after first immunisation 10 days
Brucella abortus vaccine A19, subcutaneous injection immune cattle, immunizing dose is 60,000,000,000 CFU/ part, according to the work before vaccine inactivation
Bacterium number calculates.
Embodiment 8
A kind of method for present embodiments providing brucella vaccine immune cattle, includes the following steps：
(a) first immunisation：Immune cattle brucella vaccine A19 vaccine inoculates 10,000,000,000 CFU/ part；
(b) secondary immunity：Brucella abortus vaccine A19 is used into formalin-inactivated, by the ox of inactivation after first immunisation 5 days
Brucella vaccine A19, subcutaneous injection immune cattle, immunizing dose is 80,000,000,000 CFU/ part, according to the viable bacteria before vaccine inactivation
Number calculates.
Embodiment 9
A kind of method for present embodiments providing brucella vaccine immune cattle, includes the following steps：
(a) first immunisation：Immune cattle brucella vaccine A19 vaccine inoculates 10,000,000,000 CFU/ part；
(b) secondary immunity：Brucella abortus vaccine A19 is used into formalin-inactivated, by inactivation after first immunisation 50 days
Brucella abortus vaccine A19, subcutaneous injection immune cattle, immunizing dose is 30,000,000,000 CFU/ part, according to the work before vaccine inactivation
Bacterium number calculates.
Embodiment 10
A kind of method for present embodiments providing brucella vaccine immune cattle, the difference from embodiment 1 is that exempting from for the first time
Epidemic disease uses Brucella melitensis vaccine Rev.1 vaccine, and secondary immunity uses the Brucella melitensis epidemic disease using formalin-inactivated
Seedling Rev.1 vaccine.
Embodiment 11
A kind of method for present embodiments providing brucella vaccine immune cattle, the difference from embodiment 1 is that exempting from for the first time
Epidemic disease uses Brucella suis vaccine S2 vaccine, and secondary immunity uses the Brucella suis vaccine using formalin-inactivated
S2, the mode being administered twice are oral.
Embodiment 12
A kind of method for present embodiments providing brucella vaccine immune cattle, the difference from embodiment 1 is that exempting from for the first time
Epidemic disease uses 45/20 vaccine of Brucella abortus, and secondary immunity uses the Brucella abortus vaccine using formalin-inactivated
A19。
Embodiment 13
A kind of method for present embodiments providing brucella vaccine immune cattle, includes the following steps：
(a) first immunisation：Immune cattle brucella vaccine A19 vaccine inoculates 10,000,000,000 CFU/ part；
(b) secondary immunity：After first immunisation 25 days, brucella outer membrane protein Omp31 subunit is immunized in secondary immunity
50mg/ parts of vaccine, using Freund's adjuvant as immunologic adjuvant；
(c) it is immunized three times：Same step (b)；
(d) four times it is immune：Same step (b).
Comparative example 1
This comparative example provides a kind of method of brucella vaccine immune cattle, the difference from embodiment 1 is that exempting from for the first time
Epidemic disease dosage is 50,000,000,000 CFU/ part.
Comparative example 2
This comparative example provides a kind of method of brucella vaccine immune cattle, the difference from embodiment 1 is that exempting from for the first time
Epidemic disease dosage is 1,000,000,000 CFU/ part.
Comparative example 3
This comparative example provides a kind of method of brucella vaccine immune cattle, the difference from embodiment 1 is that only carrying out
First immunisation.
Comparative example 4
This comparative example provides a kind of method of brucella vaccine immune cattle, the difference from embodiment 1 is that secondary exempt from
When epidemic disease, Brucella abortus vaccine A19 is without inactivation treatment.
Effect example 1
Every group of experimental animal is 10-15 bull, when 4 monthly age according to above-described embodiment and comparative example offer method into
Row is immune, and challenge viral dosage is carried out after 8 months, and slaughter carries out Experimental Comparison after 2 months, as a result as shown in the table.
Table 1 is immunized bull and attacks the Infected with Brucella rate after poison
As can be seen from the above table, the method for brucella vaccine immune cattle provided in an embodiment of the present invention is mentioned better than comparative example
The method of confession.Optimize the immunizing dose of vaccine it can be seen from the comparison of embodiment 1- embodiment 7 and the time being separated by is immunized twice
Immune effect can be optimized；Although being greater than by embodiment 1 and the dosage of 8 secondary immunity of comparative example it can be seen from the comparison of embodiment 8
Comparative example 1, but infection rate is reduced there is no corresponding, therefore It is not necessary in secondary immunity from the point of view of actual production
When excessive dosage is added, first increase control and prevention of disease cost, second increase ox there is the risk of stress reaction；By embodiment 1
Dosage is very few when can be seen that secondary immunity with the comparison of embodiment 9 is also unfavorable for ox generation immune response；By embodiment 1 and in fact
A 10-13 comparison is applied as can be seen that the immune effect of Brucella abortus vaccine A19 in some embodiments is better than other types
Vaccine；By embodiment 1 and the comparison of comparative example 1 it can be seen that secondary immunity is better than the effect of primary immunization, and in being immunized
Ox occur stress adverse reaction.Answering, also occurs in comparative example 3 co-injection Brucella abortus vaccine A19 live vaccine twice
Sharp adverse reaction.Can to sum up it illustrate, the method for brucella vaccine immune cattle provided by the invention is due to primary immunization work
Live vaccine is repeatedly immunized in vaccine.
Effect example 2
Brucellosis morbidity cattle farm 6-8 monthly age calf 100 is chosen, every 50 are one group, and first group according to comparative example 1
Scheme is immunized, and second group of scheme according to embodiment 1 is immunized.Two groups of test ox carry out isolated rearing, measure it and exempt from
Temperature changing on the 14th after epidemic disease inoculation, observes pregnancy rate, abortion ratio 2-3, wherein pregnancy rate and abortion ratio are as shown in table 2, body temperature
Variation is as depicted in figs. 1 and 2.
Pregnancy and Abortion Results statistical form after 2 test ox of table is immune
From this experiment as can be seen that the scheme that embodiment 1 provides acts on more preferably the brucellosis prevention and control of cow, it is immunized
Biennium pregnancy rate is higher afterwards and abortion ratio is lower, and after immunization protocol provided by the invention ox body temperature it is more steady
It is fixed, illustrate that immunization method provided by the invention lower can cause the level of stress reaction of ox.
Finally it should be noted that：The above embodiments are only used to illustrate the technical solution of the present invention., rather than its limitations；To the greatest extent
Present invention has been described in detail with reference to the aforementioned embodiments for pipe, those skilled in the art should understand that：Its according to
So be possible to modify the technical solutions described in the foregoing embodiments, or to some or all of the technical features into
Row equivalent replacement；And these are modified or replaceed, various embodiments of the present invention technology that it does not separate the essence of the corresponding technical solution
The range of scheme.
Claims (10)
1. a kind of method of brucella vaccine immune cattle, which is characterized in that the immunization method includes first immune using vaccine A
Ox is primary, then reuses vaccine B immune cattle at least once；
Wherein, the vaccine A is Brucella live vaccine；The immunizing dose of the Brucella live vaccine is hundred million CFU/ of 60-150
Head part；
The vaccine B includes inactivated vaccine, subunit vaccine, recombinant protein vaccine, polypeptide vaccine and the DNA vaccination of brucella
At least one of.
2. the method for brucella vaccine immune cattle according to claim 1, which is characterized in that brucella epidemic disease living
The dosage of seedling is 80-130 hundred million CFU/ part.
3. the method for brucella vaccine immune cattle according to claim 2, which is characterized in that brucella epidemic disease living
The dosage of seedling is 90-110 hundred million CFU/ part.
4. the method for brucella vaccine immune cattle according to claim 1, which is characterized in that the vaccine A includes ox
Brucella vaccine A19, Brucella melitensis vaccine Rev.1, Brucella suis vaccine S2, Brucella abortus 45/20 or rough type
B. abortus strain 51.
5. the method for brucella vaccine immune cattle according to claim 1, which is characterized in that first time immune cattle 10-
Vaccine B immune cattle is reused after 40 days, it is preferably 15-35 days, 20-30 days more preferable.
6. the method for brucella vaccine immune cattle according to any one of claims 1-5, which is characterized in that use epidemic disease
Seedling B immune cattle 1-3 times.
7. the method for brucella vaccine immune cattle according to claim 6, which is characterized in that use vaccine B immune cattle
Once, the vaccine B is inactivated vaccine.
8. the method for brucella vaccine immune cattle according to claim 7, which is characterized in that the inactivated vaccine is will
The inactivated vaccine obtained after vaccine A inactivation.
9. the method for brucella vaccine immune cattle according to claim 8, which is characterized in that the brucella inactivation
The dosage of vaccine is 400-600 hundred million CFU/ part, and the dosage of brucella inactivated vaccine is according to the viable count meter before vaccine inactivation
It calculates；
Preferably, the dosage of the brucella inactivated vaccine is 450-550 hundred million CFU/ part；
Preferably, the dosage of the brucella inactivated vaccine is 480-500 hundred million CFU/ part.
10. a kind of method of brucella vaccine immune cattle of any of claims 1-9 is anti-in the brucella of ox
Purposes in control.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811096575.2A CN108812548A (en) | 2018-09-19 | 2018-09-19 | The method and purposes of brucella vaccine immune cattle |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811096575.2A CN108812548A (en) | 2018-09-19 | 2018-09-19 | The method and purposes of brucella vaccine immune cattle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108812548A true CN108812548A (en) | 2018-11-16 |
Family
ID=64149388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811096575.2A Pending CN108812548A (en) | 2018-09-19 | 2018-09-19 | The method and purposes of brucella vaccine immune cattle |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108812548A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111796091A (en) * | 2020-07-20 | 2020-10-20 | 天康生物股份有限公司 | Kit for distinguishing brucella infection or brucella ghost vaccine of animals |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101016541A (en) * | 2006-12-26 | 2007-08-15 | 中国农业科学院兰州兽医研究所 | Method of producing brucella vaccine antigen protein |
| CN101581726A (en) * | 2009-03-26 | 2009-11-18 | 张晓艳 | New-generation brucellosis antibody competition enzyme-linked immunosorbent adsorption test detection kit |
| CN101592661A (en) * | 2009-03-26 | 2009-12-02 | 张晓艳 | The brucellosis antibody competition enzyme-linked immunosorbent adsorption test detection kit |
| CN101704890A (en) * | 2009-11-13 | 2010-05-12 | 烟台绿叶动物保健品有限公司 | Preparation method of duck hepatitis antibody |
| WO2013012875A2 (en) * | 2011-07-18 | 2013-01-24 | Mount Sinai School Of Medicine | Bacterial rnas as vaccine adjuvants |
| CN103221064A (en) * | 2011-11-23 | 2013-07-24 | 苏州工业园区唯可达生物科技有限公司 | Immune methods against influenza viruses and combinatorial vaccines thereof |
| CN102617731B (en) * | 2012-04-19 | 2014-02-26 | 华中农业大学 | Porcine circovirus-resistant type 2 egg yolk antibody and preparation method and application thereof |
| WO2015118541A1 (en) * | 2014-02-05 | 2015-08-13 | Gavish-Galilee Bio Applications Ltd | A genetic system for generating conditionally inactivated or attenuated bacteria |
| CN105999253A (en) * | 2016-05-11 | 2016-10-12 | 内蒙古华希生物科技有限公司 | Brucellosis vaccine needle-free injection system and application |
-
2018
- 2018-09-19 CN CN201811096575.2A patent/CN108812548A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101016541A (en) * | 2006-12-26 | 2007-08-15 | 中国农业科学院兰州兽医研究所 | Method of producing brucella vaccine antigen protein |
| CN101581726A (en) * | 2009-03-26 | 2009-11-18 | 张晓艳 | New-generation brucellosis antibody competition enzyme-linked immunosorbent adsorption test detection kit |
| CN101592661A (en) * | 2009-03-26 | 2009-12-02 | 张晓艳 | The brucellosis antibody competition enzyme-linked immunosorbent adsorption test detection kit |
| CN101704890A (en) * | 2009-11-13 | 2010-05-12 | 烟台绿叶动物保健品有限公司 | Preparation method of duck hepatitis antibody |
| WO2013012875A2 (en) * | 2011-07-18 | 2013-01-24 | Mount Sinai School Of Medicine | Bacterial rnas as vaccine adjuvants |
| CN103221064A (en) * | 2011-11-23 | 2013-07-24 | 苏州工业园区唯可达生物科技有限公司 | Immune methods against influenza viruses and combinatorial vaccines thereof |
| CN102617731B (en) * | 2012-04-19 | 2014-02-26 | 华中农业大学 | Porcine circovirus-resistant type 2 egg yolk antibody and preparation method and application thereof |
| WO2015118541A1 (en) * | 2014-02-05 | 2015-08-13 | Gavish-Galilee Bio Applications Ltd | A genetic system for generating conditionally inactivated or attenuated bacteria |
| CN105999253A (en) * | 2016-05-11 | 2016-10-12 | 内蒙古华希生物科技有限公司 | Brucellosis vaccine needle-free injection system and application |
Non-Patent Citations (2)
| Title |
|---|
| 刘维娟: "布鲁菌病研究进展", 《农业科技与信息》 * |
| 英特威（香港）有限公司: "《禽病防治手册》", 31 May 1997, 中国科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111796091A (en) * | 2020-07-20 | 2020-10-20 | 天康生物股份有限公司 | Kit for distinguishing brucella infection or brucella ghost vaccine of animals |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7351527B2 (en) | Immunizing fish against viral infection | |
| CN106148287B (en) | Porcine epidemic diarrhea virus strain and vaccine composition, preparation method and application thereof | |
| CN107320720A (en) | A kind of vaccine combination, kit and application | |
| CN110117576B (en) | Duck adenovirus type-3 virus strain and preparation and application of yolk antibody thereof | |
| CN105462936B (en) | A kind of Porcine epidemic diarrhea virus MY01 plants and its application | |
| CN106554944A (en) | The vaccine combination and application of pig epidemic diarrhea virus attenuated strain and its preparation | |
| CN113493775B (en) | Porcine delta coronavirus strain and application thereof | |
| RU2442603C2 (en) | Vaccine against blue tongue virus and immunogenic compositions, methods of their application and production | |
| CN108220248A (en) | Porcine rotavirus strain, vaccine composition and its preparation method and application | |
| CN111876391A (en) | Feline panleukopenia virus FPV BJ05 strain and application thereof | |
| CN113491767A (en) | Triple inactivated vaccine for duck circovirus disease, novel duck reovirus disease and duck viral hepatitis and preparation method thereof | |
| CN109467606A (en) | A kind of escherichia coli enterotoxin STa-LTB-STb fusion protein and its encoding gene and application | |
| CN102010876A (en) | Recombinant bacillus subtilis EV71-VP1 expression vector and preparation method and application thereof | |
| CN104371025A (en) | Immunogenic protein aiming at cervical cancer and application of immunogenic protein | |
| CN111808826B (en) | Porcine type-A seneca virus SVA/CH-Fuj strain and application thereof | |
| CN111729091B (en) | Method for checking efficacy of porcine Seika virus inactivated vaccine by using rabbit | |
| CN108812548A (en) | The method and purposes of brucella vaccine immune cattle | |
| CN105400745A (en) | Porcine reproductive and respiratory syndrome virus (PRRSV) genetic engineering strain, inactivated vaccine thereof, and preparation method of inactivated vaccine | |
| CN101235363B (en) | Pig transmissible gastroenteritis virus vaccine strain and application thereof | |
| CN104988107A (en) | Recombinant lactic acid bacillus efficiently expressing foot and mouth disease virus antigen genes and preparation method and application thereof | |
| CN104800842B (en) | A kind of goatpox, sheep pox divalence cell weak-toxic vaccine and its preparation method and application | |
| CN106039304B (en) | Porcine parvovirus, porcine epidemic diarrhea and Escherichia coli triple vaccine | |
| US3479430A (en) | Indirect passive immunization against transmissible gastroenteritis virus in nursing piglets at birth by active immunization of sows prior to farrowing with transmissible gastroenteritis vaccine and method of producing the same | |
| CN116121202A (en) | Coxsackie virus B group 1 strain and application thereof | |
| CN105497885B (en) | A kind of subunit vaccine and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181116 |